UY23572A1 - Empleo de inhibidores de activadores de plasminógeno para el tratamiento de inflamaciones y heridas. - Google Patents
Empleo de inhibidores de activadores de plasminógeno para el tratamiento de inflamaciones y heridas.Info
- Publication number
- UY23572A1 UY23572A1 UY23572A UY23572A UY23572A1 UY 23572 A1 UY23572 A1 UY 23572A1 UY 23572 A UY23572 A UY 23572A UY 23572 A UY23572 A UY 23572A UY 23572 A1 UY23572 A1 UY 23572A1
- Authority
- UY
- Uruguay
- Prior art keywords
- treatment
- inhibitors
- pai
- lesions
- inflammatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere al empleo de inhibidores de activadores de plasminógeno para la preparación de un medicamento para la terapia y/o profilaxis de inflamaciones de los ojos, de los oídos, de la piel, de los huesos, de las articulaciones, del intestino o de otros órganos internos y/o para el tratamiento intraoperativo y/o postoperativo y/o para el tratamiento de heridas abiertas. Los activadores del plasminógeno son uroquinasa y/o tPA. Los inhibidores son PAI-1 y/o PAI-2, preferiblemente fragmentos de PAI-2. Se utilizan en el tratamiento de úlcera córnea, uveítis, conjuntivitis, otitis media, agrietamiento de la membrana del tímpano con evolución inflamatoria, eritemas de la piel, eczema, dermatitis por contacto, osteoartritis, enfermedad inflamatoria del intestino, pancreatitis, acné, tratamiento de lesiones epiteliales, tratamiento de la cicatrización en el caso de lesiones de los ojos, entre otras lesiones inflamatorias.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4214215A DE4214215A1 (de) | 1992-04-30 | 1992-04-30 | Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen |
Publications (1)
Publication Number | Publication Date |
---|---|
UY23572A1 true UY23572A1 (es) | 1993-05-04 |
Family
ID=6457814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY23572A UY23572A1 (es) | 1992-04-30 | 1993-04-27 | Empleo de inhibidores de activadores de plasminógeno para el tratamiento de inflamaciones y heridas. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0567816A1 (es) |
JP (1) | JPH069425A (es) |
KR (1) | KR930021179A (es) |
CN (1) | CN1080873A (es) |
AU (1) | AU3822993A (es) |
CA (1) | CA2095207A1 (es) |
CZ (1) | CZ76893A3 (es) |
DE (1) | DE4214215A1 (es) |
HU (1) | HUT65755A (es) |
IL (1) | IL105521A0 (es) |
MX (1) | MX9302519A (es) |
NO (1) | NO931561L (es) |
PL (1) | PL298748A1 (es) |
SK (1) | SK41593A3 (es) |
UY (1) | UY23572A1 (es) |
ZA (1) | ZA933023B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5468505A (en) * | 1992-02-28 | 1995-11-21 | Board Of Regents, The University Of Texas System | Local delivery of fibrinolysis enhancing agents |
GB2271507A (en) * | 1992-09-04 | 1994-04-20 | Summit Technology Ireland Bv | Compositions containing plasmin activity inhibitors |
US5994341A (en) * | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
DE69434048T2 (de) * | 1993-07-19 | 2005-10-06 | Angiotech Pharmaceuticals, Inc., Vancouver | Anti-angiogene Mittel und Verfahren zu deren Verwendung |
US6558798B2 (en) | 1995-02-22 | 2003-05-06 | Scimed Life Systems, Inc. | Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity |
US5939525A (en) * | 1995-03-27 | 1999-08-17 | Viron Therapeutics, Inc. | Methods of treating inflammation and compositions therefor |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US20040254635A1 (en) | 1998-03-30 | 2004-12-16 | Shanley John F. | Expandable medical device for delivery of beneficial agent |
US6241762B1 (en) | 1998-03-30 | 2001-06-05 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
JP2002526382A (ja) * | 1998-04-01 | 2002-08-20 | バイオテック・オーストラリア・ピーティーワイ・リミテッド | 皮膚創傷の治療へのプロテアーゼ阻害剤の使用 |
US6293967B1 (en) | 1998-10-29 | 2001-09-25 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US6120847A (en) * | 1999-01-08 | 2000-09-19 | Scimed Life Systems, Inc. | Surface treatment method for stent coating |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
WO2000066139A2 (en) * | 1999-04-29 | 2000-11-09 | Ista Pharmaceuticals, Inc. | Biochemical methods that eliminate corneal scars, opacification and haze |
US6156373A (en) | 1999-05-03 | 2000-12-05 | Scimed Life Systems, Inc. | Medical device coating methods and devices |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
JP3690720B2 (ja) | 1999-09-14 | 2005-08-31 | インターナショナル・ビジネス・マシーンズ・コーポレーション | クライアントサーバーシステム、オブジェクトのプール方法および記憶媒体 |
PT1223971E (pt) | 1999-10-27 | 2005-10-31 | Alexandra Lucas | Composicoes e metodos para prevencao e tratamento da rejeicao de transplante |
JP2001247458A (ja) * | 2000-03-08 | 2001-09-11 | Hamari Chemicals Ltd | トラネキサム酸亜鉛化合物を含む糖尿病治療剤 |
AU2001291579B2 (en) | 2000-09-29 | 2006-08-31 | Viron Therapeutics Inc. | Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions |
KR100819895B1 (ko) | 2000-10-16 | 2008-04-07 | 코너 메드시스템즈 인코포레이티드 | 약제 전달용 팽창 가능한 의료 장치 |
US6764507B2 (en) | 2000-10-16 | 2004-07-20 | Conor Medsystems, Inc. | Expandable medical device with improved spatial distribution |
US20040073294A1 (en) | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
AT500019B1 (de) * | 2001-06-27 | 2007-06-15 | Inst Gefaessbiologie Und Throm | Verwendung in vitro des transkriptionsfaktors nak-1 oder von nak-1 regulierten genen zur diagnose von entzündlichen und malignen erkrankungen |
GB0126389D0 (en) * | 2001-11-02 | 2002-01-02 | Pfizer Ltd | Wafer |
US7785653B2 (en) | 2003-09-22 | 2010-08-31 | Innovational Holdings Llc | Method and apparatus for loading a beneficial agent into an expandable medical device |
US7285530B2 (en) | 2004-10-21 | 2007-10-23 | Viron Therapeutics, Inc. | Use of SERP-1 as an antiplatelet agent |
US20090202524A1 (en) * | 2007-10-31 | 2009-08-13 | Alcon Research, Ltd. | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
BRPI0906167A2 (pt) * | 2008-01-21 | 2018-05-22 | Dermadis S A | uso de inibidor de serina protease no tratamento de doenças de pele. |
TWI763960B (zh) * | 2017-12-15 | 2022-05-11 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種預防或治療骨關節炎的方法及藥物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3829523A1 (de) * | 1988-08-31 | 1990-03-01 | Behringwerke Ag | Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression |
DK0458937T3 (da) * | 1989-12-20 | 1998-02-23 | Biotech Australia Pty Ltd | Varianter af PAI-2 |
EP0451130A3 (en) * | 1990-04-05 | 1992-08-05 | Baltimore Biotech, Inc. | Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization |
-
1992
- 1992-04-30 DE DE4214215A patent/DE4214215A1/de not_active Withdrawn
-
1993
- 1993-04-08 EP EP19930105801 patent/EP0567816A1/de not_active Withdrawn
- 1993-04-27 UY UY23572A patent/UY23572A1/es unknown
- 1993-04-27 IL IL105521A patent/IL105521A0/xx unknown
- 1993-04-28 CZ CZ93768A patent/CZ76893A3/cs unknown
- 1993-04-28 SK SK415-93A patent/SK41593A3/sk unknown
- 1993-04-28 KR KR1019930007154A patent/KR930021179A/ko not_active Application Discontinuation
- 1993-04-28 JP JP5101636A patent/JPH069425A/ja active Pending
- 1993-04-29 CA CA002095207A patent/CA2095207A1/en not_active Abandoned
- 1993-04-29 PL PL29874893A patent/PL298748A1/xx unknown
- 1993-04-29 NO NO93931561A patent/NO931561L/no unknown
- 1993-04-29 ZA ZA933023A patent/ZA933023B/xx unknown
- 1993-04-29 CN CN93105253A patent/CN1080873A/zh active Pending
- 1993-04-29 AU AU38229/93A patent/AU3822993A/en not_active Abandoned
- 1993-04-29 MX MX9302519A patent/MX9302519A/es unknown
- 1993-04-30 HU HU9301272A patent/HUT65755A/hu unknown
Also Published As
Publication number | Publication date |
---|---|
HUT65755A (en) | 1994-07-28 |
MX9302519A (es) | 1993-10-01 |
NO931561L (no) | 1993-11-01 |
AU3822993A (en) | 1993-11-04 |
SK41593A3 (en) | 1993-11-10 |
KR930021179A (ko) | 1993-11-22 |
IL105521A0 (en) | 1993-08-18 |
ZA933023B (en) | 1994-10-31 |
NO931561D0 (no) | 1993-04-29 |
EP0567816A1 (de) | 1993-11-03 |
DE4214215A1 (de) | 1993-11-04 |
PL298748A1 (en) | 1993-12-27 |
HU9301272D0 (en) | 1993-07-28 |
CN1080873A (zh) | 1994-01-19 |
CZ76893A3 (en) | 1994-01-19 |
JPH069425A (ja) | 1994-01-18 |
CA2095207A1 (en) | 1993-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY23572A1 (es) | Empleo de inhibidores de activadores de plasminógeno para el tratamiento de inflamaciones y heridas. | |
Mosbech et al. | Mortality from and risk of gastric carcinoma among patients with pernicious anaemia | |
ES2352350T3 (es) | Nuevas composiciones farmacéuticas que contienen ácido hialurónico o sus derivados y colagenasa para el tratamiento de heridas, quemaduras y úlceras. | |
ES2167377T3 (es) | Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos. | |
CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
Reitberger et al. | Argon cold plasma–a novel tool to treat therapy-resistant corneal infections | |
BR0316776A (pt) | Formula para anti-infeccioso tópico | |
Rhody | Bacterial infections of the skin | |
RU2008102249A (ru) | Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания | |
ES2758372T3 (es) | Composición para su uso en el tratamiento de infecciones bacterianas | |
Klein et al. | Wound infection following trauma and burn injuries | |
US8507652B2 (en) | Pharmaceutical composition, dressing and method for treating skin lesion, intermediate composition and process for preparing said dressing, and use of cerium salt associated with a collagen matrix | |
Datarkar et al. | Management of soft tissue injuries in the maxillofacial region | |
Cannon et al. | Rate of epithelial regeneration: a clinical method of measurement, and the effect of various agents recommended in the treatment of burns | |
WO2016054757A1 (es) | Composición farmacéutica para prevenir, tratar y curar la rosácea que comprende baba de caracol, manzanilla y propóleo | |
Eiferman | Cryotherapy of Pseudomonas keratitis and scleritis | |
NO960525L (no) | Terapeutisk preparat | |
Santos et al. | Bilateral pseudocyst of the auricle in an infant girl | |
EP1663195B1 (en) | Taurine bromamine for inhibiting pathogenic bacteria and fungi growth as well as in a microbicidal composition | |
Perry et al. | Reconstruction of ear deformity from post-piercing perichondritis | |
Rattan et al. | Management of ocular adnexal trauma | |
US20070010582A1 (en) | Use of N-chlorotaurine for treatment of oozing tissue deficiencies | |
Tamura et al. | Literature review: Auricular disorders Part 1-physical and thermal change related traumas | |
Lever et al. | Management of Ocular Adnexal Trauma | |
US20080207750A1 (en) | Use of N-Chlorotaurine for Treatment of Oozing Tissue Deficiencies |